Developer docs
API playgroundTry for free, no card

Search company profiles

Axolotl Biosciences

Full company profile

uuid000a835

Namestring
Axolotl Biosciences
Legal namestring
Axolotl Biosciences
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Axolotl Biosciences is a privately held Canadian biotechnology company founded in 2020 and headquartered in Victoria, British Columbia, as a spin-off from the University of Victoria's bioprinting research group. The company develops and sells TissuePrint, a research-grade, xeno-free, fibrin-based bioink for 3D bioprinting of human tissue models. Its product line includes a Low Viscosity (LV) formulation optimized for microfluidic bioprinters such as the Aspect Biosystems RX1, a High Viscosity (HV) formulation for extrusion-based bioprinters such as the CELLINK BIOX, and a complementary TissuePrint Crosslinker; all kits support human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), with constructs reported to maintain high cell viability for over a month in culture.

The company's technology has been validated through peer-reviewed publications in journals including ACS Biomaterials, Materials Today Chemistry, and Frontiers in Bioengineering, with demonstrated applications in drug screening, neural tissue engineering, glioblastoma tumor modeling, and neurocardiac systems. Axolotl sells its products directly through an e-commerce storefront with global shipping, priced at $500 per bioink kit and $100 per crosslinker, and supplements product sales with consulting services for bioprinting lab setup and bioink validation. Its core customers are academic researchers and biotechnology companies, and it has established technology partnerships with major bioprinter manufacturers (CELLINK, Aspect Biosystems, Allevi3D) and is supported by non-dilutive funding from Canadian programs including InnovateBC, Mitacs, MSFHR, IRAP, NSERC, and ventureLAB.

Short descriptiontext

Axolotl Biosciences is a Victoria, BC-based University of Victoria spin-off that develops and sells xeno-free TissuePrint fibrin-based bioinks for 3D bioprinting of human tissue models to academic researchers and biotechnology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVictoria, Canada
HQ citystring
Victoria
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioprinting bioinks, 3D tissue printing, tissue engineering reagents, bioprinting consumables, stem cell bioinks
Industry2 codes
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bioprinting Bioinks
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Bioink Product Sales
TypeOne Time License
Description

Direct e-commerce sales of TissuePrint bioink kits (LV and HV formulations) and crosslinkers to academic researchers and biotechnology companies globally.

axolotlbiosciences.com
2Consulting Services
TypeProfessional Services
Description

Consulting services offered for bioprinting needs including setting up new lab spaces and testing bioinks on various bioprinters. Customers contact via email to discuss requirements.

axolotlbiosciences.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details3 tiers
1TissuePrint-LV Kit - Low viscosity bioink for microfluidic bioprinters
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$500.00 per kit. Includes components to make 5mL of bioink and 20mL of crosslinker.

axolotlbiosciences.com
2TissuePrint-HV Kit - High viscosity bioink for extrusion bioprinters
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$500.00 per kit. Includes components to make 5mL of bioink and 20mL of crosslinker.

axolotlbiosciences.com
3TissuePrint Crosslinker - Xeno-free crosslinker component
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$100.00 per crosslinker kit. Includes components to make 20mL of crosslinker.

axolotlbiosciences.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1TissuePrint
Description

A fibrin-based bioink product line for 3D bioprinting of human tissue models, available in high viscosity (HV) and low viscosity (LV) formulations.

axolotlbiosciences.com
Core offering1 text field

Axolotl Biosciences develops and sells fibrin-based bioink kits (TissuePrint-LV and TissuePrint-HV) and complementary crosslinkers used in 3D bioprinting of human tissue models. The xeno-free bioinks support multiple cell lines including human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), and are compatible with leading extrusion and microfluidic bioprinters. The company also offers consulting services for bioprinting lab setup and bioink testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Cell viability maintained at 98% at day 7 post-printing with guggulsterone microspheres
+2 more records
Product overview1 text field

Axolotl Biosciences offers a portfolio of TissuePrint bioink products centered around their proprietary fibrin-based bioink technology for 3D bioprinting of human tissue models. The product line consists of two main bioink formulations—TissuePrint-LV (Low Viscosity) for microfluidic bioprinters and TissuePrint-HV (High Viscosity) for extrusion-based bioprinters—along with a complementary TissuePrint Crosslinker. Both bioink kits include components to make 5mL of bioink and 20mL of crosslinker. The company also provides consulting services for bioprinting needs. All products are research-grade, xeno-free, and designed to support hiPSCs, neural progenitor cells, and mesenchymal stem cells for drug development and tissue engineering applications.

Product and service4 records
1TissuePrint-LV Kit
CategoryBioprinting Bioinks
Description

A research-grade, xeno-free, fibrin-based bioink with low viscosity formulation optimized for microfluidic-based bioprinters such as the Aspect Biosystems RX1. Supports hiPSCs, neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs). Each kit includes components to make 5mL of bioink and 20mL of crosslinker.

2TissuePrint-HV Kit
CategoryBioprinting Bioinks
Description

A research-grade, xeno-free, fibrin-based bioink with high viscosity formulation optimized for extrusion-based bioprinters such as the CELLINK BIOX. Supports hiPSCs, neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs). Each kit includes components to make 5mL of bioink and 20mL of crosslinker.

3TissuePrint Crosslinker
CategoryBioprinting Consumables
Description

A research-grade, xeno-free crosslinker that pairs with both High Viscosity and Low Viscosity TissuePrint Bioinks. Used alongside bioink in the bioprinting process to create printable fibers for building 3D constructs. Recommended use of 20mL of crosslinker for every 5mL of bioink; each crosslinker kit includes components to make 20mL of crosslinker.

4Bioprinting Consulting Services
CategoryConsulting Services
Description

Consulting services for bioprinting needs, including assistance setting up new lab spaces and testing bioinks on a wide range of bioprinters. Customers contact the company via email to discuss requirements.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Aspect Biosystems
Strategic tierCoreTypeTechnology or Integration
Description

Aspect Biosystems is a bioprinter manufacturer whose RX1 microfluidic bioprinter is optimized for use with Axolotl Biosciences' TissuePrint-LV (Low Viscosity) bioink. Their technology is used in published research studies demonstrating the bioink's effectiveness for neural tissue engineering and neurocardiac system modeling.

axolotlbiosciences.com
Strategic tierCoreTypeTechnology or Integration
Description

CELLINK is a bioprinter manufacturer whose BIOX extrusion-based bioprinter is optimized for use with Axolotl Biosciences' TissuePrint-HV (High Viscosity) bioink. The partnership enables compatibility between the bioink and CELLINK's bioprinting platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Aspect Biosystems
TypeDirect peer
Description

Aspect Biosystems manufactures the RX1 microfluidic bioprinter for which Axolotl's TissuePrint-LV is the optimized bioink, while also developing its own tissue-therapeutic programs. It is a direct peer because it sells into the same 3D-bioprinting-for-tissue-modeling category and overlaps with Axolotl on bioink supply for the RX1 platform.

TypeEmerging player
Description

Brinter is a smaller bioprinter manufacturer offering modular extrusion-based bioprinters and partnering with bioink developers. It is a peer because its printers are an alternative platform on which customers run bioinks, and its bioink-compatibility ecosystem partially overlaps with the multi-platform strategy behind TissuePrint.

TypeDirect peer
Description

Regemat3D designs and sells extrusion-based bioprinters and develops its own line of bioinks and bioink components (including personalized bioinks for regenerative medicine). It is comparable to Axolotl because it competes in the bioink + bioprinter consumables market and serves similar academic and translational research customers.

TypeBroad incumbent
Description

3D Systems is a large, publicly-traded additive-manufacturing company whose healthcare arm has historically included bioprinting and tissue-engineering activities. It is a broad incumbent comparable to Axolotl at the industry/category level — operating in 3D bioprinting — but with a far broader product portfolio and not specialized in fibrin-based bioinks.

TypeDirect peer
Description

Rokit Healthcare develops 3D bioprinters, bioinks, and bio-fabrication workflows for regenerative medicine, including skin, cartilage, and bone tissue applications. It is comparable to Axolotl because it sells both bioprinters and proprietary bioinks into overlapping tissue-engineering and regenerative-medicine research markets.

TypeDirect peer
Description

Organovo is a 3D-bioprinting and tissue-engineering company that has historically sold bioprinted human tissue models and partnered on bioink development. It is comparable because it operates in the same 3D-bioprinting-for-human-tissue-modeling market that Axolotl's TissuePrint products serve.

TypeDirect peer
Description

CollPlant develops and commercializes recombinant human-collagen-based bioinks and 3D-bioprinting tissue products for regenerative medicine. It is directly comparable to Axolotl because both companies sell bioink consumables for 3D bioprinting of human tissue models and target researchers and therapeutic developers in tissue engineering.

TypeDirect peer
Description

Poietis develops laser-assisted 3D bioprinting platforms and bioink formulations for tissue engineering and regenerative medicine, including partnerships with major cosmetics and pharma players. It is a direct peer to Axolotl in the bioink/bioprinter-for-tissue-models category with overlapping customer use cases in drug discovery and tissue engineering.

TypeDirect peer
Description

BICO/CELLINK is the dominant player in the 3D bioprinting ecosystem and sells both bioprinters (incl. BIOX, which Axolotl's TissuePrint-HV is optimized for) and a broad portfolio of competing bioinks. It is directly comparable because it operates in the same horizontal bioink market, targets overlapping academic/biopharma customers, and competes head-to-head on the same printer platforms.

10BioBots (now part of BICO/Allevi)
TypeDirect peer
Description

Allevi (formerly BioBots, part of BICO) sells extrusion-based bioprinters (the Allevi 3D platform that Axolotl's TissuePrint is compatible with) and its own line of bioinks. It is a direct peer competing in the same academic/research bioink-and-bioprinter market that Axolotl addresses with TissuePrint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Axolotl Biosciences

Bioprinting Bioinksaxolotlbiosciences.com

Axolotl Biosciences is a Victoria, BC-based University of Victoria spin-off that develops and sells xeno-free TissuePrint fibrin-based bioinks for 3D bioprinting of human tissue models to academic researchers and biotechnology companies.

What Axolotl Biosciences does

Axolotl Biosciences is a privately held Canadian biotechnology company founded in 2020 and headquartered in Victoria, British Columbia, as a spin-off from the University of Victoria's bioprinting research group. The company develops and sells TissuePrint, a research-grade, xeno-free, fibrin-based bioink for 3D bioprinting of human tissue models. Its product line includes a Low Viscosity (LV) formulation optimized for microfluidic bioprinters such as the Aspect Biosystems RX1, a High Viscosity (HV) formulation for extrusion-based bioprinters such as the CELLINK BIOX, and a complementary TissuePrint Crosslinker; all kits support human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), with constructs reported to maintain high cell viability for over a month in culture.

The company's technology has been validated through peer-reviewed publications in journals including ACS Biomaterials, Materials Today Chemistry, and Frontiers in Bioengineering, with demonstrated applications in drug screening, neural tissue engineering, glioblastoma tumor modeling, and neurocardiac systems. Axolotl sells its products directly through an e-commerce storefront with global shipping, priced at $500 per bioink kit and $100 per crosslinker, and supplements product sales with consulting services for bioprinting lab setup and bioink validation. Its core customers are academic researchers and biotechnology companies, and it has established technology partnerships with major bioprinter manufacturers (CELLINK, Aspect Biosystems, Allevi3D) and is supported by non-dilutive funding from Canadian programs including InnovateBC, Mitacs, MSFHR, IRAP, NSERC, and ventureLAB.

Axolotl Biosciences firmographics

Firmographics
Name
Axolotl Biosciences
Legal name
Axolotl Biosciences
Website
https://axolotlbiosciences.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Axolotl Biosciences is a Victoria, BC-based University of Victoria spin-off that develops and sells xeno-free TissuePrint fibrin-based bioinks for 3D bioprinting of human tissue models to academic researchers and biotechnology companies.
Ownership category
akta.pro rank

Axolotl Biosciences industry classification

Industry
Product category
Bioprinting Bioinks
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Bioprinting bioinks
  • 3D tissue printing
  • Tissue engineering reagents
  • Bioprinting consumables
  • Stem cell bioinks

Where Axolotl Biosciences is headquartered

Location

Headquarters

HQ city
Victoria
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Axolotl Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Bioink Product Sales: Direct e-commerce sales of TissuePrint bioink kits (LV and HV formulations) and crosslinkers to academic researchers and biotechnology companies globally.
  2. Consulting Services: Consulting services offered for bioprinting needs including setting up new lab spaces and testing bioinks on various bioprinters. Customers contact via email to discuss requirements.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goTissuePrint-LV Kit - Low viscosity bioink for microfluidic bioprinters
Unit PricingPay-as-you-goTissuePrint-HV Kit - High viscosity bioink for extrusion bioprinters
Unit PricingPay-as-you-goTissuePrint Crosslinker - Xeno-free crosslinker component

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Axolotl Biosciences product offering

Product offering

Core offering

Axolotl Biosciences develops and sells fibrin-based bioink kits (TissuePrint-LV and TissuePrint-HV) and complementary crosslinkers used in 3D bioprinting of human tissue models. The xeno-free bioinks support multiple cell lines including human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), and are compatible with leading extrusion and microfluidic bioprinters. The company also offers consulting services for bioprinting lab setup and bioink testing.

Product overview

Axolotl Biosciences offers a portfolio of TissuePrint bioink products centered around their proprietary fibrin-based bioink technology for 3D bioprinting of human tissue models. The product line consists of two main bioink formulations—TissuePrint-LV (Low Viscosity) for microfluidic bioprinters and TissuePrint-HV (High Viscosity) for extrusion-based bioprinters—along with a complementary TissuePrint Crosslinker. Both bioink kits include components to make 5mL of bioink and 20mL of crosslinker. The company also provides consulting services for bioprinting needs. All products are research-grade, xeno-free, and designed to support hiPSCs, neural progenitor cells, and mesenchymal stem cells for drug development and tissue engineering applications.

Differentiator

Problem solved

Functional benefit

Brands

  • TissuePrint: A fibrin-based bioink product line for 3D bioprinting of human tissue models, available in high viscosity (HV) and low viscosity (LV) formulations.

Products and services

  • TissuePrint-LV Kit A research-grade, xeno-free, fibrin-based bioink with low viscosity formulation optimized for microfluidic-based bioprinters such as the Aspect Biosystems RX1. Supports hiPSCs, neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs). Each kit includes components to make 5mL of bioink and 20mL of crosslinker.
  • TissuePrint-HV Kit A research-grade, xeno-free, fibrin-based bioink with high viscosity formulation optimized for extrusion-based bioprinters such as the CELLINK BIOX. Supports hiPSCs, neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs). Each kit includes components to make 5mL of bioink and 20mL of crosslinker.
  • TissuePrint Crosslinker A research-grade, xeno-free crosslinker that pairs with both High Viscosity and Low Viscosity TissuePrint Bioinks. Used alongside bioink in the bioprinting process to create printable fibers for building 3D constructs. Recommended use of 20mL of crosslinker for every 5mL of bioink; each crosslinker kit includes components to make 20mL of crosslinker.
  • Bioprinting Consulting Services Consulting services for bioprinting needs, including assistance setting up new lab spaces and testing bioinks on a wide range of bioprinters. Customers contact the company via email to discuss requirements.

Quantifiable outcome

  • Cell viability maintained at 98% at day 7 post-printing with guggulsterone microspheres
  • +2 more outcomes

Companies that use Axolotl Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Axolotl Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature7 records

Axolotl Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Aspect BiosystemscoreTechnology or IntegrationAspect Biosystems is a bioprinter manufacturer whose RX1 microfluidic bioprinter is optimized for use with Axolotl Biosciences' TissuePrint-LV (Low Viscosity) bioink. Their technology is used in published research studies demonstrating the bioink's effectiveness for neural tissue engineering and neurocardiac system modeling.
  • CELLINKcoreTechnology or IntegrationCELLINK is a bioprinter manufacturer whose BIOX extrusion-based bioprinter is optimized for use with Axolotl Biosciences' TissuePrint-HV (High Viscosity) bioink. The partnership enables compatibility between the bioink and CELLINK's bioprinting platform.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Axolotl Biosciences competitors and assessment

Company assessment

Direct peers

  • Aspect Biosystems: Aspect Biosystems manufactures the RX1 microfluidic bioprinter for which Axolotl's TissuePrint-LV is the optimized bioink, while also developing its own tissue-therapeutic programs. It is a direct peer because it sells into the same 3D-bioprinting-for-tissue-modeling category and overlaps with Axolotl on bioink supply for the RX1 platform.
  • Regemat3D: Regemat3D designs and sells extrusion-based bioprinters and develops its own line of bioinks and bioink components (including personalized bioinks for regenerative medicine). It is comparable to Axolotl because it competes in the bioink + bioprinter consumables market and serves similar academic and translational research customers.
  • Rokit Healthcare: Rokit Healthcare develops 3D bioprinters, bioinks, and bio-fabrication workflows for regenerative medicine, including skin, cartilage, and bone tissue applications. It is comparable to Axolotl because it sells both bioprinters and proprietary bioinks into overlapping tissue-engineering and regenerative-medicine research markets.
  • Organovo Holdings: Organovo is a 3D-bioprinting and tissue-engineering company that has historically sold bioprinted human tissue models and partnered on bioink development. It is comparable because it operates in the same 3D-bioprinting-for-human-tissue-modeling market that Axolotl's TissuePrint products serve.
  • CollPlant Biotechnologies: CollPlant develops and commercializes recombinant human-collagen-based bioinks and 3D-bioprinting tissue products for regenerative medicine. It is directly comparable to Axolotl because both companies sell bioink consumables for 3D bioprinting of human tissue models and target researchers and therapeutic developers in tissue engineering.
  • Poietis: Poietis develops laser-assisted 3D bioprinting platforms and bioink formulations for tissue engineering and regenerative medicine, including partnerships with major cosmetics and pharma players. It is a direct peer to Axolotl in the bioink/bioprinter-for-tissue-models category with overlapping customer use cases in drug discovery and tissue engineering.
  • CELLINK (BICO): BICO/CELLINK is the dominant player in the 3D bioprinting ecosystem and sells both bioprinters (incl. BIOX, which Axolotl's TissuePrint-HV is optimized for) and a broad portfolio of competing bioinks. It is directly comparable because it operates in the same horizontal bioink market, targets overlapping academic/biopharma customers, and competes head-to-head on the same printer platforms.
  • BioBots (now part of BICO/Allevi): Allevi (formerly BioBots, part of BICO) sells extrusion-based bioprinters (the Allevi 3D platform that Axolotl's TissuePrint is compatible with) and its own line of bioinks. It is a direct peer competing in the same academic/research bioink-and-bioprinter market that Axolotl addresses with TissuePrint.

Emerging players

  • Brinter: Brinter is a smaller bioprinter manufacturer offering modular extrusion-based bioprinters and partnering with bioink developers. It is a peer because its printers are an alternative platform on which customers run bioinks, and its bioink-compatibility ecosystem partially overlaps with the multi-platform strategy behind TissuePrint.

Broad incumbents

  • 3D Systems: 3D Systems is a large, publicly-traded additive-manufacturing company whose healthcare arm has historically included bioprinting and tissue-engineering activities. It is a broad incumbent comparable to Axolotl at the industry/category level — operating in 3D bioprinting — but with a far broader product portfolio and not specialized in fibrin-based bioinks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Axolotl Biosciences social profiles

Digital presence

Axolotl Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Axolotl Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Axolotl Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Axolotl Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axolotl Biosciences

What does Axolotl Biosciences do?

Axolotl Biosciences develops and sells fibrin-based bioink kits (TissuePrint-LV and TissuePrint-HV) and complementary crosslinkers used in 3D bioprinting of human tissue models. The xeno-free bioinks support multiple cell lines including human induced pluripotent stem cells (hiPSCs), neural progenitor cells (NPCs), and mesenchymal stem cells (MSCs), and are compatible with leading extrusion and microfluidic bioprinters. The company also offers consulting services for bioprinting lab setup and bioink testing.

Is Axolotl Biosciences a public or private company?

Axolotl Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Axolotl Biosciences founded?

Axolotl Biosciences was founded in 2020. It employs 1 to 10 people.

Where is Axolotl Biosciences based?

Axolotl Biosciences is headquartered in Victoria, Canada, in the North America region.

How does Axolotl Biosciences make money?

Two revenue lines are on record. Bioink Product Sales are the primary driver. The others are consulting Services.

Who are Axolotl Biosciences's main competitors?

Direct peers on record are Aspect Biosystems, Regemat3D, Rokit Healthcare, Organovo Holdings, CollPlant Biotechnologies, Poietis, CELLINK (BICO) and BioBots (now part of BICO/Allevi). Brinter is listed as an emerging player. 3D Systems is listed as a broad incumbent.

Does Axolotl Biosciences have an API?

No public API is recorded for Axolotl Biosciences.

What industry is Axolotl Biosciences in?

Axolotl Biosciences's product category is Bioprinting Bioinks. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Association for Manufacturing TechnologyWhat a Startup Challenge Says About Trends in Additive ManufacturingThe 2024 Formnext Start-up Challenge highlighted a continued industry shift toward targeted additive manufacturing applications, particularly in healthcare, with winners Axolotl Biosciences and Oryx Medicals focusing on bioprinting for drug testing and patient-specific heart valves. Established player 3D Systems reported double-digit revenue growth in its personalized healthcare segment while industrial solutions declined, reinforcing the trend toward application-driven solutions over core technology development. Other companies like Conflux Technology and Norsk Titanium are also leveraging additive manufacturing for specialized industrial and aerospace components.Trust & Safety PoliciesMeet the Round 4 BC Fast AwardeesInnovate BC and NRC IRAP announced the latest cohort of awardees for the BC Fast Pilot program, which supports regional SMEs in demonstrating their technologies in real-world conditions. This initiative has invested $7.9 million into 62 pilot demonstrations since its inception in 2019, with the new round featuring companies such as Axolotl Biosciences, CRWN.ai, and GRT.Innovate BCMeet the Round 4 BC Fast AwardeesInnovate BC and NRC IRAP have announced the latest group of awardees for the BC Fast Pilot program, which supports regional SMEs in demonstrating their technologies in real-world conditions. This initiative has invested $7.9 million into 62 pilot demonstrations since its inception in 2019, with the new round featuring projects from companies such as Axolotl Biosciences, CRWN.ai, and GRT.